Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1156)	5/6/2002 8:57:16 PM
From: michael_f_murphy	Read Replies (4) \| Respond to of 2243

HCV circa 2010 of $3B future value at that time with 15% approval chance and 15%/yr discount is about $140M present value. RSV circa 2009 of $700M future value with 15% chance and 15%/yr is about $40M present value. I swag the debt drag at -$60M present value. Net 140M+40-60=120M or about $5.25/shr of which the HCV program is more than 100% of net value so I would say that it is leveraged. How long 'til wheels come off (again)? 4Q02 as bitty biotech waits on big pharma for clinical trial progress?